Tim FitzSimons' practice focuses on public and private M&A with an emphasis on friendly and unsolicited tender offers, and he has advised companies on transactions totaling more than US$100 billion. Tim represents directors in conflict of interest transactions and corporate governance and shareholder activism/takeover defense matters. He also has represented private equity and venture capital investors and portfolio companies in financing and general company representation matters and financial advisors in M&A transactions, working with bulge bracket and boutique investment banks.

Prior to joining Jones Day in 2015, Tim advised the Special Committee of the Board of Directors of Genentech in its US$46.8 billion merger with Roche Holdings (pursuant to a tender offer) and CBOT Holdings in its US$12 billion merger with Chicago Mercantile Exchange Holdings (including the intervening unsolicited offer from InterContinental Exchange). He also has advised, among many others, Energy Transfer in its US$5.3 billion cash and stock acquisition of Sunoco and in its $9.4 billion cash and stock acquisition of Southern Union Company (including the competing offer from the Williams Group); Orbitz in its 2004 sale pursuant to a US$1.2 billion tender offer by Cendant Corporation and again in its 2015 US$1.4 billion sale to Expedia; Eli Lilly in its US$6.5 billion tender offer for ImClone Systems; and the Koch Industries family of companies in more than $10 billion of acquisitions.

Tim regularly speaks and writes on M&A topics, including articles on developments in public company M&A matters, activist hedge funds, and corporate governance matters.